09 Mar
  • By Brandon
  • Cause in

NS Pharma is launching expanded access for viltolarsen

CureDuchenne is excited to share that NS Pharma is launching expanded access for viltolarsen, allowing patients with DMD amenable to exon 53 skipping to receive this product while it is being reviewed by the FDA. CureDuchenne thanks NS Pharma for showing dedication to the DMD community by opening access to this treatment merely weeks after FDA’s […]

READ MORE
03 Mar
  • By Brandon
  • Cause in

IMPORTANT ANNOUNCEMENT ON UPCOMING CURE DUCHENNE CARES EVENTS

3/13/2020: UPDATED ANNOUNCEMENT AVAILABLE HERE » We never want to put anyone from the Duchenne community at risk, and with the statements from the CDC regarding travel risks, especially for persons with compromised immune systems, we want to let everyone know that we will be changing the format and dates of some of our upcoming in-person […]

READ MORE